Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as XmAb412 Monoclonal Bispecific Antibody
XmAb412 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: Active Drug | ACTIVE_COMPARATOR | Active XmAb412 to be administered to healthy adult participants. |
| Part A: Placebo | PLACEBO_COMPARATOR | Placebo Comparator to be administered to healthy participants. |
| Part B: Active | ACTIVE_COMPARATOR | Active XmAb412 to be administered to healthy participants. |
| Part B: Placebo | PLACEBO_COMPARATOR | Placebo Comparator to be administered to healthy participants. |
| Name | Type | Description |
|---|---|---|
| XmAb412 Monoclonal Bispecific Antibody | DRUG | Monoclonal Bispecific Antibody |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Age 18-55 years old * Must be in good health with no significant medical history * BMI 18-35 kg/m2 * Contraceptive use consistent with local regulations * Able and willing to provide written informed consent Exclusion Criteria: * Any physical condition that prohibits study c...
XmAb412 is an investigational monoclonal bispecific antibody developed by Xencor, Inc. It is being studied in a Phase 1 clinical trial in healthy adult participants, rather than in patients with a specific disease. The program is in early clinical development, with one recruiting trial listed.
XmAb412 targets IL23p19, a protein subunit of the cytokine interleukin-23. By binding this target, the bispecific antibody is designed to engage IL23p19 as part of its investigational mechanism. Xencor is evaluating this targeted approach in a Phase 1 study in healthy volunteers.
Xencor, Inc. is developing XmAb412. Xencor trades on the Nasdaq under the ticker XNCR. The company is the sponsor of the Phase 1 study of XmAb412 in healthy adult participants.
XmAb412 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The single registered trial is a Phase 1 study in healthy adult participants, and it is currently recruiting.
XmAb412 is being studied in one clinical trial, NCT07713485, titled Study of XmAb412 in Healthy Participants. The Phase 1 trial is recruiting 128 healthy adult participants in Australia. It is randomized, double blind, and placebo controlled, and it enrolls participants aged 18 years and older.
Yes. XmAb412 Monoclonal Bispecific Antibody is another name for XmAb412, the investigational antibody developed by Xencor, Inc. Both names refer to the same Phase 1 asset being evaluated in healthy adult participants under trial NCT07713485.